Literature DB >> 15297937

Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?

Valerie W Rusch1.   

Abstract

Recent epidemiological shifts have led to controversy about the etiology and treatment of gastroesophageal (GE) junction adenocarcinomas. The Siewert classification conveniently describes the anatomical location of these tumors relative to the GE junction. However, available data suggest that there may be epidemiological, clinical, and molecular differences among GE junction adenocarcinomas, depending on whether they are predominantly esophageal or gastric in location. Much more investigation is required to confirm or refute these apparent differences, which can affect clinical treatment.

Entities:  

Mesh:

Year:  2004        PMID: 15297937     DOI: 10.1053/j.seminoncol.2004.04.023

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

1.  The histological appearance of oesophageal adenocarcinoma--an analysis based on 215 resection specimens.

Authors:  Mario Sarbia
Journal:  Virchows Arch       Date:  2006-02-24       Impact factor: 4.064

Review 2.  The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer.

Authors:  Elizabeth Cartwright; David Cunningham
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 3.  Chemotherapy for advanced gastric cancer.

Authors:  Anna Dorothea Wagner; Nicholas Lx Syn; Markus Moehler; Wilfried Grothe; Wei Peng Yong; Bee-Choo Tai; Jingshan Ho; Susanne Unverzagt
Journal:  Cochrane Database Syst Rev       Date:  2017-08-29

Review 4.  Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease.

Authors:  Matthew F Buas; Thomas L Vaughan
Journal:  Semin Radiat Oncol       Date:  2013-01       Impact factor: 5.934

5.  Vitamin E intake and risk of esophageal and gastric cancers in the NIH-AARP Diet and Health Study.

Authors:  Sarah Carman; Farin Kamangar; Neal D Freedman; Margaret E Wright; Sanford M Dawsey; L Beth Dixon; Amy Subar; Arthur Schatzkin; Christian C Abnet
Journal:  Int J Cancer       Date:  2009-07-01       Impact factor: 7.396

6.  Tumors of the gastroesophageal junction have intermediate prognosis compared to tumors of the esophagus and stomach, but share the same clinical determinants.

Authors:  Paolo G Gobbi; Manuela Bergonzi; Donatella Pozzoli; Lara Villano; Alessandro Vanoli; Franco Corbella; Paolo Dionigi; Gino R Corazza
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

Review 7.  Esophageal Cancer: Insights From Mouse Models.

Authors:  Marie-Pier Tétreault
Journal:  Cancer Growth Metastasis       Date:  2015-08-16

Review 8.  Clinical management of gastroesophageal junction tumors: past and recent evidences for the role of radiotherapy in the multidisciplinary approach.

Authors:  Francesco Cellini; Alessio G Morganti; Francesco M Di Matteo; Gian Carlo Mattiucci; Vincenzo Valentini
Journal:  Radiat Oncol       Date:  2014-02-05       Impact factor: 3.481

9.  A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.

Authors:  Cong Wang; Dong-Jian Song; Zhi-Li Xu; Shu-Ping Xie; Jun-Hong Hu
Journal:  Exp Mol Med       Date:  2017-09-29       Impact factor: 8.718

Review 10.  Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation.

Authors:  Francesco Cellini; Stefania Manfrida; Calogero Casà; Angela Romano; Alessandra Arcelli; Alice Zamagni; Viola De Luca; Giuseppe Ferdinando Colloca; Andrea D'Aviero; Lorenzo Fuccio; Valentina Lancellotta; Luca Tagliaferri; Luca Boldrini; Gian Carlo Mattiucci; Maria Antonietta Gambacorta; Alessio Giuseppe Morganti; Vincenzo Valentini
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.